INEM
Home  |   About INEM  |   Projects  |   Tools  |   Contact  |   Legal information

Novartis delivery of child-friendly antimalarial hits the 100 million mark - 27 February 2012.

One hundred million treatments of Coartem Dispersible (artemether-lumefantrine), an antimalarial developed especially for children with Plasmodium falciparum malaria, have been delivered by Novartis to 39 malaria-endemic countries, Medicines for Malaria Venture (MMV) announced. CoartemĀ® Dispersible is the product of the partnership between MMV and Novartis.

This is the first who prequalified child-friendly artemisinin-combination therapy (ACT) and addresses an unmet need for pediatric medicines. Young children in Africa are disproportionately affected by malaria, with 86% of malaria deaths occurring in children under the age of 5 years.

 

Source: www.csreurope.org

February 27  2012.